SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register

@@start.t1@@--------------------------------------------------------------------------------   Corporate news transmitted by euro adhoc. The issuer/originator is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Capital measures

Heidelberg (euro adhoc) - SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register

Heidelberg,  15  December  2010  -  SYGNIS  Pharma  AG  (Frankfurt:   LIO;    ISIN DE0005043509; Prime Standard) today announced the registration  of  the  capital reduction in the commercial register on the  basis  of  the  resolution  of  the Annual General Meeting held on 30 November 2010. Hereby  the  share  capital  is reduced from EUR 41,258,643  to  EUR  13,752,881,  allocated  to  13,752,881 shares outstanding.

At the same time the implementation  of  the  capital  reduction  on the  stock exchange and the consolidation of the shares in a 3:1 ratio were  initiated.  It is expected that the consolidation of the shares will be completed  by  the  end of December 2010. Due to this process the trading of the SYGNIS  shares  on  the stock exchange will be temporarily suspended.

The purpose of this capital reduction is  primarily  to  improve  the Company´s abilities  to  interact  on  the  capital  markets  and  to open  up  financing alternatives, since the Company´s share price has been below the  nominal  value of EUR 1 for a long period. It is anticipated that this move will better support the development of the shares.

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,   is  a  specialty  pharmaceutical company listed on the Prime Standard of the German stock exchange.  The  Company is focused on the research and  development  of  innovative  therapies  for  the treatment of disorders of the Central Nervous System. SYGNIS´ core projects  are currently Acute Stroke for which SYGNIS´ lead clinical programme  is  AX200  as well as the preclinical KIBRA-project for the treatment of  different  forms  of dementia. All these disorders are  characterized  by  the  fact  that,  as  the disease progresses, nerve cells are damaged and die.  Although  there  is  great medical demand, there are currently no  or  only  inadequate  treatment   options available. SYGNIS´ strategy for growth includes the development of new  products from its own research and through in-licensing and acquisitions.

For further information please contact: SYGNIS Pharma AG: Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812

Media-Contact: Julia Phillips Financial Dynamics Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this  press  release,   relating  neither  to  proven financial results nor other  historical data,  should  be  viewed  as  forward- looking, i.e. not definite. Such statements are  mainly  predictions  of  future results, trends, plans or goals. These statements should not  be  considered  to be total guarantees since given their very nature they are subject to known  and unknown risks and imponderability and can be affected  by other  factors  as  a consequence of which the actual results, plans and goals  of  SYGNIS  Pharma  AG may deviate greatly from the   established  conclusions  or  implied  predictions contained in such statements. SYGNIS does not undertake to  publicly  update  or revise these statements in the light of new information  or  future  results or for any other reason.  ###

@@start.t2@@end of announcement                                                 euro adhoc

Further inquiry note: Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX, Prime All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Hamburg / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              Hannover / free trade
              München / free trade

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: